×
About 161,988 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
https://clinicaltrials.gov/ct2/show/NCT03412565

Aug 12th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

Impact of chemoprophylaxis on Plasmodium vivax and Plasmodium ovale infection among civ...
https://doi.org/10.1093/cid/ciac641
Clinical Infectious Diseases : an Official Publication Of... Le Goff M, Kendjo E et. al.

Aug 14th, 2022 - The impact of chemoprophylaxis targeting Plasmodium falciparum on Plasmodium vivax and Plasmodium ovale, which may remain quiescent as hypnozoites in the liver, is debated. We conducted a nested case-control analysis of the outcomes of P. vivax and P. ovale infections in imported malaria cases in France among civilian travellers from January 1st, 2006, to December 31st, 2017. Using adjusted log...

Massive intravascular hemolysis is an important factor in Clostridium perfringens-induc...
https://doi.org/10.1007/s11739-022-03036-3
Internal and Emergency Medicine; Suzaki A, Komine-Aizawa S et. al.

Aug 14th, 2022 - Clostridium perfringens bacteremia is rare but often fatal. In particular, once bacteremia with massive intravascular hemolysis (MIH) occurs, the mortality rate is extremely high. However, because of its rarity, the detailed pathophysiology of this fulminant form of bacteremia is unclear. To elucidate the detailed pathogenesis of MIH, we retrospectively reviewed the data of all patients with C....

Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.
https://doi.org/10.1136/bcr-2022-250009
BMJ Case Reports; Cerniglia M, Klepadlo M et. al.

Aug 13th, 2022 - For hepatocellular carcinoma, the IMbrave150 trial demonstrated that combination atezolizumab and bevacizumab had significantly better overall survival compared with sorafenib in patients with unresectable disease. However, as more immune checkpoint inhibitors are approved as first-line agents in gastrointestinal cancers, there have been few reports on whether sequential PD-1/PD-L1 blockade is ...

Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly pa...
https://doi.org/10.1007/s00432-022-04246-0
Journal of Cancer Research and Clinical Oncology; Samaran Q, Samaran R et. al.

Aug 13th, 2022 - Anti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials. To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions ...

Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future pos...
https://doi.org/10.1016/bs.acr.2022.01.012
Advances in Cancer Research; Høgdall D, O'Rourke CJ et. al.

Aug 13th, 2022 - A diagnosis of cholangiocarcinoma (CCA) is implicit with poor prognosis and limited treatment options, underscoring the near equivalence of incidence and mortality rates in this disease. In less than 9years from genomic identification to FDA-approval of the corresponding inhibitors, fibroblast growth factor receptor 2 (FGFR2) rearrangements and isocitrate dehydrogenase 1 (IDH1) mutations became...

Hepatocytes infected with hepatitis C virus change immunological features in the liver ...
https://doi.org/10.3350/cmh.2022.0032
Clinical and Molecular Hepatology; Park SJ, Hahn YS

Aug 13th, 2022 - Hepatitis C virus (HCV) infection is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antiviral agents (DAA) are promising HCV therapies to clear the virus. However, recent reports indicate potential increased risk of HCC development among HCV patients with cirrhosis following DAA therapy. CD8...

Biologic Agents in Crohn's Patients Reduce CD4+ T Cells Activation and Are Inversely Re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357708
Canadian Journal of Gastroenterology & Hepatology; Rosseto-Welter EA, D'argenio-Garcia L et. al.

Aug 13th, 2022 - Crohn's disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron's disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. In fact, in Brazil, many patients are only given the option of receiving...

Identifying RBBP7 as a Promising Diagnostic Biomarker for BK Virus-Associated Nephropathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357817
Journal of Immunology Research; Wang Y, Wang Y et. al.

Aug 13th, 2022 - BK virus-associated nephropathy (BKVN) remains a major infectious complication due to powerful immunosuppression in kidney transplant recipients, and its histologic appearance can mimic rejection, leading to diagnostic and treatment dilemmas thus molecular diagnostic methods would be beneficial. We collected gene expression profiles of 169 kidney biopsies taken from BKVN, rejection, and stable ...

Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe l...
https://doi.org/10.1177/09612033221119123
Lupus Liu D, Zhou Q et. al.

Aug 13th, 2022 - Systemic lupus erythematosus is a chronic inflammatory autoimmune disease that has various manifestations. Lupus nephritis is a common and severe presentation, which results in increased morbidity and mortality. Belimumab added on standard therapy has been proved to induce disease remission and improve renal parameters. However, the use of belimumab has not been explored in patients requiring d...

Asymptomatic Congenital CMV Treatment
https://clinicaltrials.gov/ct2/show/NCT03301415

Aug 12th, 2022 - This is a phase II, open-label trial to evaluate valganciclovir as a treatment to prevent development of sensorineural hearing loss (SNHL) in infants with asymptomatic congenital cytomegalovirus (CMV) infection. The trial will be conducted in two phases - screening of newborns to identify eligible subjects, and treatment of those newborns who have confirmed CMV infection at birth but without ou...

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for...
https://clinicaltrials.gov/ct2/show/NCT03217812

Aug 12th, 2022 - The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
https://clinicaltrials.gov/ct2/show/NCT04739800

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who ...

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04759586

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine if nivolumab + chemo-immunotherapy results in a superior long term progression-free survival (PFS) (events defined as disease progression confirmed by central review or death) when compared with chemo-immunotherapy alone in patients with newly diagnosed primary mediastinal B-cell lymphoma. SECONDARY OBJECTIVES: I. To compare the rates of "efficacy-related even...

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT02076009

Aug 12th, 2022 - This is a randomized (participants will be assigned by chance to study treatments), open-label (all participants and study personnel will know the identity of the study treatments), active-controlled (none of the study treatments are placebo), parallel-group (both treatment arms will run at the same time), multicenter study. In this study, daratumumab, lenalidomide, and low-dose dexamethasone (...

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT04730583

Aug 12th, 2022 - This study will evaluate the tolerability and effectiveness of four FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site.

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT04039464

Aug 12th, 2022 - A Phase III, randomized, open label, pragmatic trial to compare the safety and efficacy of first-line combination therapy (sildenafil and bosentan) to first-line monotherapy (sildenafil alone) in pediatric subjects with WHO Functional Classes II or III and precapillary pulmonary hypertension of Group 1 (PAH caused by idiopathic, heritable, drugs or toxins, congenital heart disease, or connectiv...

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04023526

Aug 12th, 2022 - AML is a heterogeneous disease characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts harvested from newly diagnosed AML participants expressed Cluster of Differentiation (CD) 70 on the cell surface. Cusatuzumab (JNJ-74494550...

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Partic...
https://clinicaltrials.gov/ct2/show/NCT04923893

Aug 12th, 2022 - Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the production of monoclonal immunoglobulin (Ig) proteins or protein fragments (M proteins) that have lost their function. JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) is an autologous chimeric antigen receptor T cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surfa...